IPP Bureau
Teva files FDA application for once-monthly schizophrenia injection
By IPP Bureau - December 11, 2025
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
Lilly drug cuts risk of disease progression or death by 80% in trial
By IPP Bureau - December 11, 2025
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
BioNTech and Bristol Myers Squibb report punchy early results for experimental TNBC therapy
By IPP Bureau - December 11, 2025
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Roche secures CE mark for groundbreaking Vaginitis test that promises accurate diagnosis
By IPP Bureau - December 11, 2025
Roche says its new assay “resolves this challenge by delivering accurate and specific results
Roche secures European nod for Gazyva/Gazyvaro in Lupus Nephritis patients
By IPP Bureau - December 11, 2025
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Bristol Myers Squibb unveils breakthrough Lymphoma data
By IPP Bureau - December 11, 2025
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
Novo Nordisk completes acquisition of Akero Therapeutics
By IPP Bureau - December 10, 2025
Akero became a wholly owned subsidiary of Novo Nordisk
Croda strikes strategic deal with Amino to boost global supply of high-purity amino acids
By IPP Bureau - December 10, 2025
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
Lilly to invest $6 billion in Huntsville manufacturing hub
By IPP Bureau - December 10, 2025
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Lilly moves forward with $3.56-per-share acquisition of Adverum
By IPP Bureau - December 10, 2025
Trelleborg launches Costa Rica facility to supercharge global medical device production
By IPP Bureau - December 10, 2025
The new site marks the company’s first operation in the region
Zydus launches affordable biosimilar 'Zyrifa' for cancer-related bone complications
By IPP Bureau - December 10, 2025
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Fermenta Biotech to invest Rs. 110 crore for Dahej plant expansion
By IPP Bureau - December 10, 2025
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Zydus and Formycon secure US and Canada partnership for Keytruda biosimilar
By IPP Bureau - December 10, 2025
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
.jpg "Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India")
Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India
By IPP Bureau - December 10, 2025
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
